Table 1. Clinical data from plasma donors.
| N | 72* |
| Age (years) | 63±14 |
| Female:Male | 35:37 |
| Eur:Afr:Asn:Hisp | 54:15:2:1 |
| BMI (kg m−2) | 29±7 |
| Family CVD history | 34 (6) |
| Current smoker | 39 (1) |
| Hypertension | 58 |
| Diabetes mellitus | 23 |
| Known CAD | 36 |
| Prior PCI | 21 |
| Prior CABG | 8 |
| Total cholesterol (mg dl−1) | 172±48 |
| LDL (mg dl−1) | 98±37 |
| HDL (mg dl−1) | 46±22 |
| Aspirin | 49 |
| β-blockers | 41 (1) |
| Statins | 39 |
| P2Y12 inhibitors | 21 |
| Heparin | 17 |
| p-ELISA MPO (μg l−1) | 20±16 |
| MAPS MPO (μg l−1) | 14±13 |
| CHL MPO (pM) | 330±140 |
Afr, African; Asn, Asian; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CVD, cardiovascular disease; ELISA, enzyme-linked immunosorbent assay; Eur, European; FDA, Food and Drug Administration; Hisp, Hispanic; MAPS, MPO activity on a polymer surface; MPO, myeloperoxidase; PCI, percutaneous coronary intervention.
Mean±s.d. are given when applicable. Parentheses indicate absent patient data. p-ELISA refers to the parallel-protocol ELISAs modified to approximate the MAPS protocol as closely as possible and eliminate systematic error. CHL is the FDA-approved MPO assay performed independently by the Cleveland HeartLab.
*CHL N=67 due to limited sample volume.